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Abstract
Background: The association between admission hyperglycemia and adverse outcomes in patients with non-ST-
segment elevation myocardial infarction (NSTEMI) undergoing percutaneous coronary intervention (PCI) has not
been well studied, and the optimal plasma glucose cut-off values for prognosis for NSTEMI patients with and
without diabetes have not been determined.
Methods: According to glucose level and diabetes status, consecutive NSTEMI patients undergoing PCI (n = 890)
were divided into four groups: without diabetes mellitus (DM) and admission plasma glucose (APG) <144 or
≥144 mg/dL; or with DM and APG <180 or ≥180 mg/dL. All patients were followed up at 30 days and 3 years after
discharge, and the outcomes were assessed.
Results: Admission hyperglycemia was found in 44 and 28% of the DM and non-DM patients, respectively.
Multivariable analyses showed that the APG level was an independent predictor of 30-day and 3-year MACEs.
Receiver operating characteristic curve analysis revealed that the appropriate cut-off values were 178 and 145
mg/dL for patients with and without DM, respectively, or 157 mg/dL for all patients.
Conclusions: Admission hyperglycemia may be used to predict 30-day and 3-year MACEs in patients with NSTEMI
undergoing PCI, irrespective of diabetes status. However, the optimal admission glucose cut-off values for
predicting prognosis differ for patients with or without DM.
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Background
Stress hyperglycemia in patients admitted with acute
myocardial infarction (AMI), with or without diabetes
mellitus (DM), has been associated with major adverse
cardiovascular events (MACE) and increased mortality
[1–3]. However, most studies have included patients
with only ST-elevation myocardial infarction (STEMI)
[2, 4, 5] or included both STEMI and non-ST-elevation
myocardial infarction (NSTEMI) patients [1, 3, 6–8].
STEMI and NSTEMI are the major types of AMI, and
each is associated with different pathophysiological
changes, complications, and prognoses [8]. Patients are
usually treated with medications [1, 5–7, 9]. Therefore,
it is also likely that the cutoff values for blood glucose
levels at admission will differ as predictors of prognoses
in these two groups.
Currently, the mainstay treatment for AMI is percutan-
eous coronary intervention (PCI). A number of studies
have sought to establish the link between blood glucose
levels at admission and adverse clinical outcomes and mor-
tality for STEMI patients undergoing PCI. For example,
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Pres et al. [10] showed that elevated random glucose levels
at admission were associated with higher in-hospital and
long-term mortality in STEMI patients undergoing pri-
mary PCI.
Similar studies performed on NSTEMI patients
undergoing primary PCI are limited (although Stefano
et al. [11] showed elderly adults with DM and random
admission hyperglycemia experienced higher mortality,
mostly due to pre-existing cardiovascular and renal
damage).
The optimal plasma glucose cut-off value for the predic-
tion of poor outcomes in NSTEMI patients has never
been determined. These values probably also differ be-
tween AMI patients with or without DM and should be
calculated separately. It may be that such a cut-off value is
higher in patients with DM, because they have higher
average glycemia. Planer et al. [12] reported that the best
predictive admission serum glucose cut-off values for 30-
day mortality in STEMI patients undergoing PCI with and
without DM were 231 and 149, respectively. Timmer et al.
[13] determined a cut-off value of 140 mg/dL for non-DM
patients with myocardial infarction.
The present study assessed the utility of admission
plasma glucose (APG) for predicting MACEs both in the
short term (30 days) and long term (3 years) in NSTEMI
patients, with and without DM, undergoing PCI. Fur-
thermore, the optimal cut-off APGs for predicting poor
outcomes in these patients were determined.
Methods
Study population
The Ethics Committee of the First Affiliated Hospital of
Xi’an Jiaotong University approved this retrospective
study, and all participants signed informed consent
forms. From January 2009 to October 2012, 890 con-
secutive NSTEMI patients undergoing PCI in two hos-
pitals in China (First Affiliated Hospital of Xi’an
Jiaotong University and Xi’an Central Hospital) were
enrolled in this study. Patients were eligible if they had
all three of the following: 1) symptoms of ischemia in-
creasing or occurring at rest, 2) an elevated cardiac tropo-
nin I level (≥2.0 ng/mL) or troponin T level (≥0.1 ng/mL)
or CK-MB (19 U/L, exceeding twice the upper limit of
normal), and 3) ischemic changes assessed by electrocardi-
ography, defined as ST-segment depression or T-wave in-
version of ≥0.2 mV in two contiguous leads. Patients were
excluded for having any of the following: STEMI; receiving
fibrinolysis therapy; no data on glucose levels as soon as
possible after admission and before the administration of
any medication; bleeding history and thrombocytopenia;
coronary artery bypass grafting (CABG) within 1 month;
drug allergy; anticoagulation contradiction; serum creatin-
ine >2.5 mg/dL; malignancy; or neurological deficit that
limited follow-up. All patients were treated according to
standard guidelines with aspirin (300 mg of chewable
preparation as a loading dose, followed by 100 mg/day),
clopidogrel (300 mg as a loading dose and then 75 mg/
day), and unfractionated heparin (5000 U as a loading
dose and then 1000 U/kg/h with a partial thromboplastin
time in the range of 50–70 s). CK-MB and troponin T or I
were detected in all patients.
Date collection and variables
The following patient data were collected and analyzed:
basic demographic and clinical characteristics (age,
gender, hypertension, diabetes, smoker, hyperlipidemia,
and pathological and therapeutic antecedents), clinical
findings on admission, laboratory tests, echocardiographic
changes, treatment during hospitalization, and treatment
after discharge. The plasma glucose values and HbA1c
levels of these patients were measured upon admission in
the local laboratory at each participating center.
DM was defined as having a previous history of DM
based on the medical institution standard diagnostic
criteria, use of diet, oral glucose-lowering medication
and/or insulin or a HbA1c ≥6.5%. This HbA1c value was
recognized by the American Diabetes Association (ADA)
as sufficient for the diagnosis of DM [14]. Hyperglycemia
was defined as any in-hospital blood glucose measurement
>140 mg/dL in accordance with the ADA consensus [15].
Admission hyperglycemia was defined as an APG con-
centration above the cut-off value, which discriminated
between good and poor prognosis and varied over a wide
range (between 6 mmol/L and 11 mmol/L) [16]. Previous
studies found that the association between high APG
levels and outcomes differed in individuals with and with-
out DM [1, 3, 17, 18], and the prognostic cut-off is
144 mg/dL (8 mmol/L) for patients without DM and
180 mg/dL (10 mmol/L) for those with DM, as shown in
the meta-analysis by Capes et al. [19]. Patients were di-
vided into the following four groups: Groups 1 and 2,
without DM and APG < or ≥144 mg/dL, respectively.
Groups 3 and 4: with DM and APG < or ≥ 180 mg/dL.
Outcomes measured
The primary objective of the present study of NSTEMI
patients undergoing PCI was to investigate the effect of
APG levels on subsequent MACEs in these patients. A
MACE was defined as any of the following: re-infarction;
heart failure requiring admission; target vessel revasculari-
zation (TVR) for recurrent ischemia or acute occlusion of
a stent; repeated PCI or coronary artery bypass grafting
(CABG); and stroke and mortality at the 30-day and 3-
year follow-ups. The secondary purpose was to determine
the optimal glucose cut-off values for predicting 30-day
mortality in diabetic and non-diabetic NSTEMI patients
undergoing PCI. Clinical follow-up variables, including re-
infarction, heart failure requiring admission, and stroke
Hao et al. BMC Cardiovascular Disorders  (2017) 17:6 Page 2 of 9
and death data, were obtained from clinic visits and tele-
phone interviews. Deaths were defined as vascular if the
death certificate stated that the underlying cause of death
was ischemic heart disease (I20-I25), stroke (I63, I64, and
I67), or other vascular diseases (I70–I79), in accordance
with the Tenth Revision of the International Classification
of Diseases (ICD-10). Otherwise, deaths were defined as
non-vascular.
All the patients were followed up at 30 days and
3 years after discharge. Clinical follow-up information
was obtained by reviewing hospital records and conduct-
ing face-to-face interviews.
Statistical analyses
Continuous variables were described as mean ± stand-
ard deviation or median (interquartile range), and dif-
ferences among the groups were determined using
Student’s t-test. Frequencies and proportions were re-
ported for categorical variables and were compared
using the chi-squared test. Multivariable Cox propor-
tional hazards regression analysis was performed to
identify the independent association between admission
glycemia and MACEs at the 30-day or 3-year follow-
ups. For all of the odds ratios (ORs), we calculated 95%
confidence intervals (CIs). Kaplan–Meier methods were
used to estimate the rates of cumulative occurrence of
MACEs at the follow-up time points and to plot the
time-to-cumulative occurrence of MACE curves. The
significance of differences among the groups was deter-
mined using the log-rank test. Receiver operating charac-
teristic (ROC) curve analyses were performed to establish
the optimal cut-off values of APG for predicting 30-day
mortality in patients with and without DM. All analyses
were performed for the entire cohort, and the significance
was established at the 0.05 level.
Results
Baseline characteristics
This study enrolled 890 patients, and 236 (26.5%) satisfied
the criteria for DM. The median (interquartile range)
APG levels were 133 (112–159) mg/dL for the entire co-
hort, 166 (138–202) mg/dL for patients with DM, and 124
(106–146) mg/dL for patients without diabetes.
There were no significant differences in mean age,
prior myocardial infarction, prior CABG, total choles-
terol, high-density lipoprotein, low-density lipoprotein,
triglyceride, creatinine, number of vessels treated, and
number of stents implanted in participants among the
four groups (Table 1).
Compared with those of Group 1, Group 2 patients
had a higher rate of Killip class 3–4, patients in Group 3
had significantly fewer women and smoking patients and
more patients treated with oral hypoglycemic agent and
insulin during hospitalization, and Group 4 patients had
significantly higher prevalences of hypertension and
hyperlipidemia, a higher rate of Killip class 3–4 and LVEF
≤40%, and were more likely to be treated with an oral
hypoglycemic agent and insulin during hospitalization
(Table 1). Compared with those of Group 2, more patients
in Group 3 and Group 4 were treated with an oral
hypoglycemic agent and insulin during hospitalization
(Table 1). In addition, no significant differences were ob-
served among these groups with regard to treatment with
aspirin, ticlopidine and clopidogrel, beta-blockers, ACEI
and ARB, statins, and CCB during hospitalization and
follow-up (Table 1).
Influence of admission hyperglycemia on short-term
MACEs
At 30 days after discharge, a higher APG was associated
with significantly higher all-cause and cardiac mortality
and heart failure requiring hospital admission, irrespective
of diabetes status, but was not correlated with the differ-
ences in the non-cardiac mortality, rates of re-infarction,
and ischemic TVR (Table 2). A significant association
between the APG and rates of stroke after discharge was
observed in patients without DM. In addition, the lowest
early all-cause and cardiac mortality rates and the inci-
dence of HF-required hospital admission and stroke were
observed in the patients of Group 1 (i.e., without DM and
APG <144 mg/dL), while the highest early all-cause and
cardiac mortality rates and the incidence of HF-required
hospital admission were observed in the patients of Group
4 (with DM and APG ≥180 mg/dL; Table 2).
Influence of admission hyperglycemia on long-term MACEs
An association between APG and MACEs was observed
early after the acute event and remained stable through
3 years of follow-up (Table 2). Higher APG was associ-
ated with a significantly higher all-cause and cardiac
mortality in patients irrespective of diabetes status, but
was not associated with non-cardiac mortality or rates
of ischemic TVR or stroke. In patients without DM, a
significant association between APG and rates of re-
infarction or heart failure requiring hospital admission
was observed. The lowest late rates of all-cause and
cardiac mortality re-infarction and heart failure requir-
ing hospital admission and stroke were observed in
Group 1 (without DM and APG <144 mg/dL), while
the highest were observed in Group 4 (with DM and
APG ≥180 mg/dL).
Survival analysis
The Kaplan–Meier survival curves showed that, com-
pared with Group 1 (without DM, APG <144 mg/dL),
Group 2 (without DM, APG ≥144 mg/dL) patients had
higher cumulative rates of MACEs at 30 days and 3 years
(Fig. 1). Compared with those in Group 3 (DM, APG
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Table 1 Baseline characteristics of NSTEMI patients stratified according to diabetic status and APG
Characteristic Participants without DM Participants with DM









Age (years) 61.0 ± 10.8 62.3 ± 11.9 62.9 ± 10.6 63.1 ± 11.6
Female (%) 87 (18.5)§ 39 (21.2)§ 44 (33.1)*# 38 (36.9)*#
Hypertension (%) 249 (53.0)§ 102 (55.4)§ 98 (73.7)*# 70 (68.0)*#
Hyperlipidemia (%) 93 (19.8) 42 (22.8) 36 (27.1) 31 (30.1)*
Smoking (%) 273 (58.1)§ 104 (56.5)§ 56 (42.1)*# 45 (43.7)*#
Prior MI (%) 54 (11.5) 25 (13.6) 19 (14.3) 15 (14.6)
Prior PCI (%) 40 (8.5)§ 24 (13)§ 30 (22.6)*# 10 (9.7)§
Prior CABG (%) 4 (0.9) 0 (0.0) 2 (1.5) 0 (0.0)
Killip class 3–4 (%) 28 (6.0)# 23 (12.5)* 14 (10.5) 17 (16.5)*
Creatinine (mg/dL) 0.87 ± 0.21 0.87 ± 0.16 0.91 ± 0.24* 0.93 ± 0.29*#
LVEF≤ 40% (%) 26 (5.5) 18 (9.8) 7 (5.3) 12 (11.7)*
TC (mg/dL) 162.6 ± 40.4 164.1 ± 40.2 160.0 ± 41.1 160.0 ± 44.5
TG (mg/dL) 139.5 ± 61.3 140.9 ± 66.4 141.5 ± 71.4 142.1 ± 65.1
HDL (mg/dL) 40.5 ± 11.8 39.0 ± 9.5 38.5 ± 12.5 39.8 ± 11.8
LDL (mg/dL) 98.6 ± 35.1 99.7 ± 33.8 92.3 ± 37.6 92.4 ± 39.0
Triple vessel disease or LM (%) 196 (41.7)§ 90 (48.9)§ 82 (61.7)*# 66 (64.1)*#
Number of vessels treated 1.45 ± 0.7 1.5 ± 0.6 1.57 ± 0.7 1.54 ± 0.7
Number of stents implanted 2.17 ± 1.3 2.33 ± 1.2 2.14 ± 1.3 2.25 ± 1.0
LAD culprit lesion (%) 203 (43.2) 91 (49.5)§ 44 (33.1)*# 41 (39.8)
TIMI 0/1flow pre‐PCI (%) 153 (32.6) 52 (28.3)§ 67 (50.4)*# 32 (31.1)§
Medication during hospitalization
Aspirin 467 (99.4) 182 (98.9) 132 (99.2) 102 (99.0)
Ticlopidine and clopidogrel 467 (99.4) 467 (99.4) 132 (99.2) 102 (99.0)
Beta-blockers 407 (86.6) 146 (79.3) 116 (87.2) 84 (82.4)
ACEI and ARB 391 (83.2) 157 (85.3) 116 (87.2) 95 (92.2)
Statins 468 (99.6) 181 (98.4) 132 (99.2) 100 (98)
CCB 45 (9.6) 22 (12.0) 13 (12.6) 13 (10.4)
Oral hypoglycemic agent 0 (0)#§ 6 (3.3)*§ 112 (84.2)*# 87 (84.5)*#
Insulin 0 (0)#§ 2 (1.1)*§ 15 (11.3)*# 20 (19.4)*#
Medication at discharge, n (%) 453 164 120 83
Aspirin 418 (92.3) 151 (92.1) 112 (93.3) 81 (97.6)
Ticlopidine and clopidogrel 56 (12.4) 18 (11.0) 13 (10.8) 11 (13.3)
Beta-blockers 254 (56.1) 108 (65.9) 76 (63.3) 50 (60.2)
ACEI and ARB 225 (49.7) 85 (51.8) 76 (63.3) 46 (55.4)
Statins 387 (85.4) 141 (86.0) 101 (84.2) 72 (86.7)
CCB 65 (14.3) 27 (16.5) 26 (21.7) 17 (20.5)
APG admission plasma glucose, MI myocardial infarction, PCI percutaneous coronary intervention, CABG coronary artery bypass graft, LVEF left-ventricular ejection
fraction, TC total cholesterol, TG triglyceride, HDL High density lipoprotein, LDL Low density lipoprotein, LM left main coronary artery, LAD left anterior descending,
TIMI thrombolysis in myocardial infarction, ACEI angiotensin converting enzyme inhibitor, ARB angiotensin receptor blocker, CCB calcium channel blocker
*P < 0.05, vs. Group 1
#P < 0.05, vs. Group 2
§P < 0.05, vs. Group 3
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<180 mg/dL), patients in Group 4 (DM, APG ≥180 mg/
dL) had higher cumulative MACE rates at 30 days and
3 years. When stratified by diabetes status and the APG
levels, the highest 30-day and 3-year cumulative MACE
rate was observed in Group 4, while the lowest was that
of Group 1.
Optimal cut-off values
Multivariate analysis revealed that an elevated APG was
an independent predictor of 30-day and 3-year MACEs,
irrespective of diabetes status (Table 3). By the ROC
analysis, the optimal cut-off values for predicting 30-day
mortality were 157 mg/dL for the entire cohort; 145 mg/
Fig. 1 The 30-day (a) and 3-year (b) cumulative occurrence of MACEs for curves in NSTEMI patients undergoing PCI stratified according to
diabetic status and admission plasma glucose (APG). Patients in Group 2 had higher cumulative occurrence rates of 30-day and 3-year MACEs.
Patients in Group 4 had higher cumulative occurrence rates of 30-day and 3-year MACEs. Groups 1 and 2: without DM, APG <144 or ≥ 144 mg/dl.
Groups 3 and 4: with DM, APG < or ≥ 180 mg/dl
Table 2 Clinical outcomes at 30 days and 3 years*
Variable Description Participants without diabetes mellitus Participants with diabetes mellitus
Group1 Group 2 Group3 Group 4









Death, all-cause 2 (0.4)*§+ 7 (3.8)*§+ 3 (2.3)#§+ 9 (8.7)#§+
Cardiac 2 (0.4)*§+ 6 (3.3)*§+ 2 (1.5)#§+ 8 (7.8)#§+
Non-cardiac 0 (0.0) 1 (0.5) 1 (0.8) 1 (1.0)
Reinfarction 0 (0.0) 1 (0.5) 1 (0.8) 1 (1.0)
HF required hospital admission 3 (0.6)*§+ 5 (2.7)*§+ 2 (1.5)#§+ 6 (5.8)#§+
Ischemic TVR 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Stroke 0 (0.0)*§ 2 (1.1)*§ 1 (0.8)§ 1 (1.0)§
3-year outcomes (%)
Death, all-cause 17 (3.6)*§+ 20 (10.9)*§+ 13 (9.8)#§+ 20 (19.4)#§+
Cardiac 14 (3.0)*§+ 17 (9.2)*§+ 12 (9.0)#§+ 19 (18.4)#§+
Non-cardiac 3 (0.6) 3 (1.6) 1 (0.8) 1 (1.0)
Reinfarction 5 (1.1)*§+ 8 (4.3)*§+ 5 (3.8)§+ 9 (8.7)§+
HF required hospital admission 16 (3.4)*§+ 22 (12.0)*§+ 15 (11.3)§+ 18 (17.5)§+
Ischemic TVR 3 (0.6) 2 (1.1) 2 (1.5) 2 (1.9)
Stroke 4 (0.9)§+ 5 (2.7)§+ 2 (1.5)§+ 5 (4.9)§+
APG admission plasma glucose, HF heart failure, TVR target lesion revascularization
*P < 0.05, Group 1 vs. Group 2
#P < 0.05, Group 3 vs. Group 4
§P < 0.05, Group 1 vs. other three groups
+P < 0.05, Group 4 vs. other three groups
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dL for patients without DM; and 178 mg/dL for patients
with DM, with areas under the curve of 0.79, 0.76, and
0.71, respectively (Fig. 2).
Discussion
The present study investigated the APG as an indicator
of the risk of short- and long-term MACEs in diabetic
and non-diabetic NSTEMI patients undergoing PCI re-
perfusion. The analysis determined that, irrespective of
diabetic status, APG could be used to predict 30-day
and 3-year MACEs. Secondly, the predictive optimal ad-
mission hyperglycemia cut-off values for 30-day mortal-
ity were 157 mg/dL for all patients (area under the curve
[AUC], 0.79), 178 mg/dL for those with DM (AUC,
0.71), and 145 mg/dL for patients without DM (AUC,
0.76).
Hyperglycemia on admission has been considered an
acute stress response [20, 21], particularly in STEMI
Table 3 Multivariable predictors of MACEs at 30 days and 3 years stratified by diabetes status
Variable B Adjusted HR [95%CI] P value
30-day MACE
All patients APG 0.016 1.016 [1.012, 1.020] <0.001
Creatinine 1.243 3.466 [1.121,10.716] 0.031
Age 0.33 1.034 [1.004,1.065] 0.028
Prior MI 1.442 4.229 [2.314,7.731] <0.001
Patients without DM APG 0.017 1.018 [1.009,1.027] <0.001
Prior MI 1.714 5.552 [2.211, 13.940] <0.001
Age 0.046 1.047 [1.004,1.092] 0.032
Patients with DM APG 0.014 1.014 [1.008,1.020] <0.001
Prior MI 1.338 3.813 [1.648,8.819] 0.002
Killip class 3-4 1.186 3.273 [1.299,8.246] 0.012
Prior PCI or CABG 1.728 5.628 [2.285,13.857] <0.001
3-year MACEs
All patients APG 0.013 1.013 [1.010,1.015] <0.001
LVEF −0.20 0.980 [0.967,0.994] 0.004
Triple vessel disease or LM 0.452 1.572 [1.149,2.151] 0.005
Beta-blockers −0.417 0.659 [0.465,0.935] 0.019
Prior MI 0.558 1.748 [1.212,2.520] 0.003
Age 0.014 1.014 [1.000,1.028] 0.043
Patients without DM APG 0.017 1.017 [1.013,1.021] <0.001
LVEF −0.029 0.972 [0.954,0.990] 0.002
Triple vessel disease or LM 0.815 2.259 [1.493,3.420] <0.001
Hypertension 0.480 1.617 [1.068,2.448] 0.023
Patients with DM APG 0.009 1.009 [1.006,1.013] <0.001
Prior MI 1.017 2.765 [1.690,4.525] <0.001
Killip class 3-4 0.637 1.891 [1.090,3.282] 0.024
Creatinine 0.961 2.614 [1.279,5.341] 0.008
APG admission plasma glucose, MACE major adverse cardiac event, DM diabetes mellitus. Other abbreviations as in Table 1
Fig. 2 ROC curves for APG mortality in all patients, with and
without diabetes
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patients with severe left ventricular dysfunction [22].
Some studies purport that hyperglycemia on admission is
causally linked to poor outcomes after AMI or is simply
an epiphenomenon related to the severity of disease. Most
recent studies have reported that admission hyperglycemia
after AMI is causally linked to further deterioration due to
myocardial damage and increased risk of death in patients,
with or without diabetes. [1–9, 12]. Yet, the clinical and
prognostic significance of high APG levels have differed
between STEMI and NSTEMI patients [8]. Since several
similar studies have been conducted on STEMI patients
[2, 4, 5], our study focused on NSTEMI patients undergo-
ing PCI, to explore the effects of APG on the rate of after
hospital discharge, and its prognostic value in the absence
or presence of DM.
The mechanisms by which hyperglycemia causes un-
favorable effects in patients with AMI are not under-
stood well. However, several studies have suggested
that a wide variety of pathophysiologic changes linked
to hyperglycemia contribute to increased mortality and
morbidity rates. It is notable that acute hyperglycemia
may exert significant hemodynamic effects even in normal
subjects. A previous study showed that plasma glucose
levels maintained at 15.0 mmol/L for 2 h in healthy sub-
jects significantly increased the mean heart rate (+9 beats
per minute), systolic and diastolic blood pressures (+20
and +14 mmHg, respectively), and plasma catecholamine
levels. These hemodynamic effects were abolished by
glutathione, a widely recognized free radical scavenger
[23], suggesting that these changes were mediated by an
oxidative-linked mechanism [24].
Stress hyperglycemia after AMI has been be associated
with endothelial and microvascular dysfunction induced
by oxidative stress and amplified inflammatory immune
reactions. Esposito et al. [25] found that circulating in-
flammatory cytokine levels closely correlated with plasma
glucose levels, that is, increasing as plasma glucose levels
increased, and immediately returning to normal as the
plasma glucose level decreased to normal. Increased
serum inflammatory cytokine concentrations may inten-
sify oxidative stress and further damage endothelial func-
tion, while reductions in circulating levels of inflammatory
cytokines were accompanied by improved endothelial
function [26].
In addition, some studies have suggested that the pro-
thrombotic state generated by hyperglycemia reduces
plasma fibrinolytic activity and activated tissue plasmino-
gen [27]. Through these mechanisms, stress hyperglycemia
after AMI is closely linked to impaired myocytes [27, 28],
impaired left ventricular function and exacerbated cardiac
damage induced by acute ischemia/reperfusion injury [29].
In conclusion, acute hyperglycemia induced by oxidative
stress, inflammation, apoptosis, endothelial dysfunction,
hypercoagulation, platelet aggregation, and impairment of
ischemic preconditioning damages the ischemic myocar-
dium. In the present study, an APG >140 mg/dL
(7.8 mmol/L) was defined as admission hyperglycemia in
accordance with the 2013 ADA Standard of Medical Care
criteria 15, which were determined based on a number of
large scale studies of the effect of glucose levels on mortal-
ity [30–33]. Our study confirmed that APG scores posi-
tively correlated with rates of MACEs in both diabetic and
non-diabetic patients.
Our study also determined the optimal cut-off APG
value for predicting short-term mortality in NSTEMI pa-
tients undergoing PCI. For assessing prognosis, stress
hyperglycemia can be defined as an APG above the cut-
off value. Such a cut-off value, determined via a ROC
curve, should differentiate patients who achieve an un-
eventful recovery from those with poor outcomes during
the observation period. In addition, for AMI patients
with DM, the prognostic cut-off value for hyperglycemia
on admission should not be the same as for non-diabetic
AMI patients, because the former have a higher average
blood glucose level [34]. Indeed, we found in the present
study that 178 mg/dL was the optimal cut-off point for
patients with DM and 145 mg/dL for the patients with-
out DM. To the best of our knowledge, our study is the
first to analyze separately the optimal cut-off APGs for
NSTEMI patients with and without DM, to predict
short-term mortality. Finally, our results suggest that el-
evated glucose levels may be an important biomarker of
increased MACEs in both diabetic and non-diabetic
patients.
Study limitations
The statistical power of the present study was limited by
the small number of patients in some of the groups.
Also, we were not able to collect data regarding liver
failure, obesity, physical activity, inflammatory markers,
or socioeconomic status, and therefore, we were not able
to adjust the analysis for these potential confounders.
Finally, although herein we reveal that hyperglycemia on
admission was associated with unfavorable short- and
long-term outcomes of both diabetic and non-diabetic
NSTEMI patients undergoing PCI treatment, the effects
of treating hyperglycemia after admission were not
assessed. Our results warrant corroboration with a study
of larger scale.
Conclusions
An elevated APG level, regardless of the diagnosis of
diabetes, results in higher short-term and long-term
poor outcomes in patients with NSTEMI undergoing
PCI. The optimal cut-off values for blood glucose in the
prognosis of patients with and without DM are different.
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